The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.68 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 23.2%. The growth in the historic period can be attributed to increasing prevalence of metabolic disorders, rising incidence of obesity and type 2 diabetes, expansion of liver disease research programs, availability of advanced diagnostic assays, growing pharmaceutical interest in nash therapies.
The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 22%. The growth in the forecast period can be attributed to increasing investments in precision hepatology, rising demand for non-invasive diagnostic tools, expansion of biomarker-driven clinical trials, growing adoption of personalized medicine approaches, increasing focus on early-stage disease management. Major trends in the forecast period include increasing development of non-invasive diagnostic biomarkers, rising use of serum-based nash biomarkers, growing integration of ai in biomarker analysis, expansion of companion diagnostics in drug development, enhanced focus on early disease detection.
The increasing incidence of liver cancer is anticipated to drive the expansion of the non-alcoholic steatohepatitis biomarkers market in the coming years. Liver cancer involves the formation of malignant tumors in the liver and may originate within the liver itself as primary liver cancer or spread from other organs as secondary or metastatic disease. Non-alcoholic steatohepatitis (NASH) biomarkers play a critical role in liver cancer by enabling early diagnosis, monitoring disease progression, and evaluating treatment response. They also provide prognostic insights and help minimize the need for invasive diagnostic procedures. For example, in July 2025, according to ecancer medical science, a United Kingdom-based oncology journal, projections indicate that global new liver cancer cases are expected to rise sharply from around 870,000 in 2022 to approximately 1.52 million by 2050, largely due to population growth and ageing, with the most significant increases forecast in Africa. Additionally, liver cancer-related deaths are projected to grow from about 760,000 in 2022 to nearly 1.37 million by 2050. As a result, the rising burden of liver cancer is contributing to the growth of the non-alcoholic steatohepatitis biomarkers market.
Leading companies in the non-alcoholic steatohepatitis biomarkers market are increasingly adopting advanced biomarker platform technologies, including multi-analyte fibrosis scoring assays, to improve non-invasive disease evaluation and patient risk stratification. These assays simultaneously measure multiple fibrosis-associated proteins from a single blood sample and apply algorithm-based analysis to generate a numerical score, supporting prognostic assessment and identification of advanced fibrosis. For instance, in July 2023, Siemens Healthineers, a Germany-based medical technology company, received Breakthrough Device Designation from the United States Food and Drug Administration for its Enhanced Liver Fibrosis Test. This multi-analyte fibrosis scoring assay is designed to aid in identifying advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease by generating a numerical score based on three direct fibrosis biomarkers. The test facilitates earlier clinical assessment of liver disease severity while reducing dependence on invasive liver biopsy procedures.
In November 2023, Alimentiv Inc., a Canada-based clinical research organization focused on precision medicine and biomarker services, entered into a partnership with AcelaBio Inc. and PharmaNest Inc. to enhance artificial intelligence-driven digital pathology capabilities for non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) clinical trials. Through this collaboration, Alimentiv aims to integrate high-throughput pathology workflows, spatial transcriptomics, and advanced AI-based biomarker quantification into its service portfolio. AcelaBio Inc. is a United States-based clinical research laboratory accredited by the College of American Pathologists, while PharmaNest Inc. is a United States-based digital pathology and artificial intelligence technology company specializing in quantitative biomarker analysis.
Major companies operating in the non-alcoholic steatohepatitis biomarkers market are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine.
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-alcoholic steatohepatitis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the non-alcoholic steatohepatitis biomarkers market by increasing costs of imported reagents, assay kits, analytical instruments, and laboratory consumables. Research institutes and pharmaceutical companies in North America and Europe are most affected due to dependence on specialized imported materials, while Asia-Pacific faces higher costs for biomarker assay development. These tariffs are raising research and diagnostic expenses. However, they are also encouraging domestic reagent production, regional laboratory supply chains, and local biomarker innovation initiatives.
The non-alcoholic steatohepatitis biomarkers market research report is one of a series of new reports that provides non-alcoholic steatohepatitis biomarkers market statistics, including non-alcoholic steatohepatitis biomarkers industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis biomarkers market share, detailed non-alcoholic steatohepatitis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis biomarkers industry. This non-alcoholic steatohepatitis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-alcoholic steatohepatitis (NASH) is a form of liver inflammation and damage resulting from the accumulation of fat in the liver. NASH biomarkers serve as diagnostic tools to evaluate the severity of non-alcoholic steatohepatitis and assess liver damage. This condition can lead to inflammation and damage to liver cells, potentially causing cirrhosis (liver scarring) and liver failure. Biomarkers, in this context, are specific qualities that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.
The primary types of NASH biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and others. Hepatic fibrosis biomarkers are specifically designed to assess hepatic fibrosis, an exaggerated wound healing response leading to excessive connective tissue formation in the liver. These biomarkers are utilized in the treatment of various diseases, including hypertension, heart disease, high blood lipids, type 2 diabetes, and obesity. NASH biomarkers find applications across various end-users, including research institutes and academics, diagnostic centers, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics, among others.
The non-alcoholic steatohepatitis biomarkers market consists of sales of biomarkers such as apolipoprotein A1, apolipoprotein B, leptin and adiponectin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 22%. The growth in the forecast period can be attributed to increasing investments in precision hepatology, rising demand for non-invasive diagnostic tools, expansion of biomarker-driven clinical trials, growing adoption of personalized medicine approaches, increasing focus on early-stage disease management. Major trends in the forecast period include increasing development of non-invasive diagnostic biomarkers, rising use of serum-based nash biomarkers, growing integration of ai in biomarker analysis, expansion of companion diagnostics in drug development, enhanced focus on early disease detection.
The increasing incidence of liver cancer is anticipated to drive the expansion of the non-alcoholic steatohepatitis biomarkers market in the coming years. Liver cancer involves the formation of malignant tumors in the liver and may originate within the liver itself as primary liver cancer or spread from other organs as secondary or metastatic disease. Non-alcoholic steatohepatitis (NASH) biomarkers play a critical role in liver cancer by enabling early diagnosis, monitoring disease progression, and evaluating treatment response. They also provide prognostic insights and help minimize the need for invasive diagnostic procedures. For example, in July 2025, according to ecancer medical science, a United Kingdom-based oncology journal, projections indicate that global new liver cancer cases are expected to rise sharply from around 870,000 in 2022 to approximately 1.52 million by 2050, largely due to population growth and ageing, with the most significant increases forecast in Africa. Additionally, liver cancer-related deaths are projected to grow from about 760,000 in 2022 to nearly 1.37 million by 2050. As a result, the rising burden of liver cancer is contributing to the growth of the non-alcoholic steatohepatitis biomarkers market.
Leading companies in the non-alcoholic steatohepatitis biomarkers market are increasingly adopting advanced biomarker platform technologies, including multi-analyte fibrosis scoring assays, to improve non-invasive disease evaluation and patient risk stratification. These assays simultaneously measure multiple fibrosis-associated proteins from a single blood sample and apply algorithm-based analysis to generate a numerical score, supporting prognostic assessment and identification of advanced fibrosis. For instance, in July 2023, Siemens Healthineers, a Germany-based medical technology company, received Breakthrough Device Designation from the United States Food and Drug Administration for its Enhanced Liver Fibrosis Test. This multi-analyte fibrosis scoring assay is designed to aid in identifying advanced fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease by generating a numerical score based on three direct fibrosis biomarkers. The test facilitates earlier clinical assessment of liver disease severity while reducing dependence on invasive liver biopsy procedures.
In November 2023, Alimentiv Inc., a Canada-based clinical research organization focused on precision medicine and biomarker services, entered into a partnership with AcelaBio Inc. and PharmaNest Inc. to enhance artificial intelligence-driven digital pathology capabilities for non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) clinical trials. Through this collaboration, Alimentiv aims to integrate high-throughput pathology workflows, spatial transcriptomics, and advanced AI-based biomarker quantification into its service portfolio. AcelaBio Inc. is a United States-based clinical research laboratory accredited by the College of American Pathologists, while PharmaNest Inc. is a United States-based digital pathology and artificial intelligence technology company specializing in quantitative biomarker analysis.
Major companies operating in the non-alcoholic steatohepatitis biomarkers market are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine.
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-alcoholic steatohepatitis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the non-alcoholic steatohepatitis biomarkers market by increasing costs of imported reagents, assay kits, analytical instruments, and laboratory consumables. Research institutes and pharmaceutical companies in North America and Europe are most affected due to dependence on specialized imported materials, while Asia-Pacific faces higher costs for biomarker assay development. These tariffs are raising research and diagnostic expenses. However, they are also encouraging domestic reagent production, regional laboratory supply chains, and local biomarker innovation initiatives.
The non-alcoholic steatohepatitis biomarkers market research report is one of a series of new reports that provides non-alcoholic steatohepatitis biomarkers market statistics, including non-alcoholic steatohepatitis biomarkers industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis biomarkers market share, detailed non-alcoholic steatohepatitis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis biomarkers industry. This non-alcoholic steatohepatitis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-alcoholic steatohepatitis (NASH) is a form of liver inflammation and damage resulting from the accumulation of fat in the liver. NASH biomarkers serve as diagnostic tools to evaluate the severity of non-alcoholic steatohepatitis and assess liver damage. This condition can lead to inflammation and damage to liver cells, potentially causing cirrhosis (liver scarring) and liver failure. Biomarkers, in this context, are specific qualities that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.
The primary types of NASH biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and others. Hepatic fibrosis biomarkers are specifically designed to assess hepatic fibrosis, an exaggerated wound healing response leading to excessive connective tissue formation in the liver. These biomarkers are utilized in the treatment of various diseases, including hypertension, heart disease, high blood lipids, type 2 diabetes, and obesity. NASH biomarkers find applications across various end-users, including research institutes and academics, diagnostic centers, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics, among others.
The non-alcoholic steatohepatitis biomarkers market consists of sales of biomarkers such as apolipoprotein A1, apolipoprotein B, leptin and adiponectin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Non-Alcoholic Steatohepatitis Biomarkers Market Characteristics
3. Non-Alcoholic Steatohepatitis Biomarkers Market Supply Chain Analysis
4. Global Non-Alcoholic Steatohepatitis Biomarkers Market Trends and Strategies
5. Non-Alcoholic Steatohepatitis Biomarkers Market Analysis of End Use Industries
7. Global Non-Alcoholic Steatohepatitis Biomarkers Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Non-Alcoholic Steatohepatitis Biomarkers Total Addressable Market (TAM) Analysis for the Market
9. Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation
10. Non-Alcoholic Steatohepatitis Biomarkers Market Regional and Country Analysis
11. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market
12. China Non-Alcoholic Steatohepatitis Biomarkers Market
13. India Non-Alcoholic Steatohepatitis Biomarkers Market
14. Japan Non-Alcoholic Steatohepatitis Biomarkers Market
15. Australia Non-Alcoholic Steatohepatitis Biomarkers Market
16. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market
17. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market
18. Taiwan Non-Alcoholic Steatohepatitis Biomarkers Market
19. South East Asia Non-Alcoholic Steatohepatitis Biomarkers Market
20. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market
21. UK Non-Alcoholic Steatohepatitis Biomarkers Market
22. Germany Non-Alcoholic Steatohepatitis Biomarkers Market
23. France Non-Alcoholic Steatohepatitis Biomarkers Market
24. Italy Non-Alcoholic Steatohepatitis Biomarkers Market
25. Spain Non-Alcoholic Steatohepatitis Biomarkers Market
26. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market
27. Russia Non-Alcoholic Steatohepatitis Biomarkers Market
28. North America Non-Alcoholic Steatohepatitis Biomarkers Market
29. USA Non-Alcoholic Steatohepatitis Biomarkers Market
30. Canada Non-Alcoholic Steatohepatitis Biomarkers Market
31. South America Non-Alcoholic Steatohepatitis Biomarkers Market
32. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market
33. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market
34. Africa Non-Alcoholic Steatohepatitis Biomarkers Market
36. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape and Company Profiles
37. Non-Alcoholic Steatohepatitis Biomarkers Market Other Major and Innovative Companies
40. Non-Alcoholic Steatohepatitis Biomarkers Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Non-Alcoholic Steatohepatitis Biomarkers Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses non-alcoholic steatohepatitis biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for non-alcoholic steatohepatitis biomarkers? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-alcoholic steatohepatitis biomarkers market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Hepatic Fibrosis Biomarkers; Serum Biomarkers; Oxidative Stress Biomarkers; Apoptosis Biomarkers; Other Types2) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA); Mass Spectrometry; Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Next-Generation Sequencing (NGS); Other Technologies
3) By End Use: Research Institutes And Academics; Diagnostic Centers; Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs); Hospitals And Clinics; Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid; Procollagen III N-terminal Propeptide (PIIINP); Fibrosis-4 (FIB-4) Index2) By Serum Biomarkers: Alanine Aminotransferase (ALT); Aspartate Aminotransferase (AST); Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA); 8-Isoprostane; Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3; Cytochrome c; Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers; Genetic Biomarkers; Inflammatory Biomarkers
Companies Mentioned: Genfit SA; Prometheus Laboratories Inc.; Siemens Medical Solutions USA Inc.; BioPredictive; Quest Diagnostics; AstraZeneca Plc.; Laboratory Corporation of America Holdings; Pfizer Inc.; Bristol-Myers Squibb Company; NGM Biopharmaceuticals Inc.; Gilead Sciences Inc.; Perspectum Diagnostics Ltd.; One Way Liver SL; Enterome SA; Echosens SA; Cisbio Bioassays SAS; Celerion Inc.; Boehringer Ingelheim GmbH Inc.; Exalenz Bioscience Ltd.; Novartis AG; Novo Nordisk A/S; Allergan PLC.; Glympse Bio; HistoIndex Pte Ltd; Cirius Therapeutics; Intercept Pharmaceuticals; Viking Therapeutics; Madrigal Pharmaceuticals; Galmed Pharmaceuticals; Immuron Ltd; Metacrine
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Non-Alcoholic Steatohepatitis Biomarkers market report include:- Genfit SA
- Prometheus Laboratories Inc.
- Siemens Medical Solutions USA Inc.
- BioPredictive
- Quest Diagnostics
- AstraZeneca Plc.
- Laboratory Corporation of America Holdings
- Pfizer Inc.
- Bristol-Myers Squibb Company
- NGM Biopharmaceuticals Inc.
- Gilead Sciences Inc.
- Perspectum Diagnostics Ltd.
- One Way Liver SL
- Enterome SA
- Echosens SA
- Cisbio Bioassays SAS
- Celerion Inc.
- Boehringer Ingelheim GmbH Inc.
- Exalenz Bioscience Ltd.
- Novartis AG
- Novo Nordisk A/S
- Allergan PLC.
- Glympse Bio
- HistoIndex Pte Ltd
- Cirius Therapeutics
- Intercept Pharmaceuticals
- Viking Therapeutics
- Madrigal Pharmaceuticals
- Galmed Pharmaceuticals
- Immuron Ltd
- Metacrine
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.08 Billion |
| Forecasted Market Value ( USD | $ 4.6 Billion |
| Compound Annual Growth Rate | 22.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
